Revealing Innate Immune Pathways to Build
ABOUT ONCHILLES PHARMA
Onchilles Pharma is a global drug discovery and development company that leverages novel neutrophil and macrophage biology to develop the next generation of immunotherapies to treat cancer. These myeloid-focused therapeutics exploit new fundamental pathways of the innate immune system and have the potential for universal anti-cancer activity, independent of genetic mutation. Based on this novel myeloid biology, Onchilles is developing a pipeline of first-in-class biologic drug candidates with the potential to be broadly effective against a wide range of cancers.
NOVEL NEUTROPHIL AND MACROPHAGE BIOLOGY EMPOWERS ANTI-TUMOR IMMUNITY
Neutrophils and macrophages are among the most abundant white blood cells in the immune system, serving as the first line of defense against infections, inflammation, and cancer. New research by Onchilles’ scientific founder, Dr. Lev Becker, uncovered that these myeloid cells are involved in fundamental pathways in aberrant cancer cells. In animal models, exploiting these innate pathways has shown to kill cancer cells at the initial tumor site and boost adaptive immunity by T cells against distant metastases. Some of these discoveries were published in Cell in June 2021
FIRST-IN-CLASS MYELOID-FOCUSED CANCER THERAPEUTICS
Onchilles is developing a pipeline of first-in-class biologic drug candidates that broadly kill cancer cells, induce immunogenic cell death, and reshape the tumor microenvironment to generate robust anti-tumor immunity. Initial in vitro and in vivo preclinical studies of the company’s first drug candidates show direct and selective anti-cancer efficacy, hallmarks of immunogenic cell death, and an immune profile supportive of systemic immunity. Onchilles is advancing proof-of-concept preclinical studies for its lead drug candidates as well as exploring these novel myeloid pathways for additional drug targets.
IN THE NEWS
DISCOVER YOUR PATH
Onchilles Pharma is looking for talented and
enthusiastic people to join our quest.